Brokerages Expect Zoetis Inc. (NYSE:ZTS) Will Post Quarterly Sales of $1.98 Billion

Wall Street brokerages predict that Zoetis Inc. (NYSE:ZTSGet Rating) will announce sales of $1.98 billion for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Zoetis’ earnings, with estimates ranging from $1.92 billion to $2.02 billion. Zoetis reported sales of $1.87 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.9%. The business is expected to report its next quarterly earnings results before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Zoetis will report full year sales of $8.45 billion for the current fiscal year, with estimates ranging from $8.40 billion to $8.48 billion. For the next fiscal year, analysts expect that the company will post sales of $9.19 billion, with estimates ranging from $8.99 billion to $9.36 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Zoetis.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings results on Tuesday, February 15th. The company reported $1.00 EPS for the quarter, beating the Zacks’ consensus estimate of $0.96 by $0.04. Zoetis had a net margin of 26.20% and a return on equity of 50.71%. The firm had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter last year, the firm earned $0.91 EPS. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year.

A number of brokerages recently commented on ZTS. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 5th. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $242.00 price target for the company. in a report on Saturday, January 8th. Finally, Citigroup decreased their price objective on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research note on Wednesday, March 9th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $224.78.

In other news, EVP Roman Trawicki sold 6,000 shares of Zoetis stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $188.15, for a total transaction of $1,128,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 2,065 shares of Zoetis stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $196.54, for a total transaction of $405,855.10. The disclosure for this sale can be found here. Insiders sold 50,455 shares of company stock worth $9,607,544 over the last ninety days. Corporate insiders own 0.21% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Financial Management Professionals Inc. purchased a new stake in Zoetis in the 3rd quarter valued at about $25,000. Investment Research & Advisory Group Inc. acquired a new position in shares of Zoetis during the fourth quarter worth about $26,000. Consolidated Planning Corp acquired a new position in Zoetis in the third quarter valued at approximately $28,000. Ogorek Anthony Joseph NY ADV acquired a new position in Zoetis in the third quarter valued at approximately $29,000. Finally, Amplius Wealth Advisors LLC purchased a new stake in Zoetis in the fourth quarter valued at approximately $31,000. 90.36% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:ZTS opened at $187.91 on Wednesday. The company has a current ratio of 3.86, a quick ratio of 2.79 and a debt-to-equity ratio of 1.45. Zoetis has a 12 month low of $161.49 and a 12 month high of $249.27. The company has a 50-day moving average price of $193.03 and a 200 day moving average price of $207.34. The company has a market cap of $88.66 billion, a price-to-earnings ratio of 44.01, a PEG ratio of 3.39 and a beta of 0.77.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 1st. Shareholders of record on Thursday, April 21st will be issued a $0.325 dividend. This represents a $1.30 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Wednesday, April 20th. Zoetis’s dividend payout ratio is currently 30.45%.

About Zoetis (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.